mycophenolate sodium / Generic mfg. - LARVOL DELTA

Anti-MDA5 Dermatomyositis Presenting With Lupus-Like Mucocutaneous Features and Inflammatory Arthritis: A Case Report. (PubMed, Case Reports Immunol) - "Initial treatment involved the administration of high-dose methylprednisolone followed by a gradual dose reduction, hydroxychloroquine, and mycophenolate sodium after the secondary skin infection resolved. Accurate diagnosis requires a comprehensive clinical and serological evaluation, as well as a deep understanding of the classification criteria for each disease to avoid overclassification. Early diagnosis and aggressive treatment targeting the primary driving pathology can improve the prognosis and quality of life of patients."

Journal • Dermatology • Dermatomyositis • Immunology • Infectious Disease • Inflammatory Arthritis • Interstitial Lung Disease • Lupus • Melanoma • Musculoskeletal Diseases • Musculoskeletal Pain • Myositis • Oncology • Pulmonary Disease • Respiratory Diseases • Rheumatoid Arthritis • Rheumatology • Solid Tumor • IFIH1

Uncontrolled Systemic Lupus Erythematosus Causing Recurrent Pancreatitis (ACG 2026) - "The patient had previously been unable to tolerate multiple immunosuppressive therapies, including azathioprine, methotrexate, mycophenolate sodium, and mycophenolate mofetil, and was not consistently following with rheumatology or receiving treatment for SLE. Rheumatology was consulted during admission, and treatment was initiated with dexamethasone, cyclophosphamide, and hydroxychloroquine...Clinicians should maintain a high index of suspicion for pancreatitis in SLE patients presenting with abdominal pain, particularly those with poorly controlled disease. This case also emphasizes the importance of consistent rheumatologic follow-up and immunosuppressive therapy, as adequate control of underlying SLE reduces the risk of recurrent pancreatic inflammation and complications."

Cardiovascular • Chronic Kidney Disease • Gastroenterology • Glomerulonephritis • Hypertension • Immunology • Inflammation • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Pancreatitis • Renal Disease • Systemic Lupus Erythematosus

A rare case of bk polyomavirus associated nephropathy in a recipient kidney transplantation: A clinical challenge in nephrology internal medicine (TTS 2026) - "Immunosuppressive therapy consisted of tacrolimus, prednisone, and mycophenolate sodium. High Tac-CV may be associated with an increased risk of BKPyV reactivation. Early modulation of immunosuppressive therapy and adjuvant IVIG may help prevent progressive graft dysfunction and long-term graft loss."

Clinical • Infectious Disease • Nephrology • Pneumonia • Renal Disease • Respiratory Diseases • Transplantation

Unexplained weight loss In renal transplantation. (TTS 2026) - "Case 2: A 28-year-old female with a live-related renal transplant (August 2021, NKD- IgA nephropathy, induction with basiliximab and maintained on standard immunosuppression, presented with rapid unintentional weight loss (24 kg over 4 months) beginning November 2024...Differential diagnoses included calcineurin inhibitor toxicity, MMF-related gastrointestinal intolerance, coeliac disease, iron overload, and adrenal insufficiency Case 1- Tacrolimus dosing was sequentially reduced, and Mycophenolate mofetil was switched to Mycophenolate sodium...In Case 2- conversion from MMF to Azathioprine was undertaken, along with measurement of 8 AM serum cortisol and anti-tTG IgA testing, there is substantial improvement of weight loss occurs up to 10 kg till follow up. These cases emphasize the need to recognize immunosuppressive toxicity as a potential cause of post-transplant weight loss, even in the absence of classical symptoms. A structured diagnostic approach and timely..."

Celiac Disease • Diabetes • Diabetic Nephropathy • Endocrine Disorders • Gastroenterology • Gastrointestinal Disorder • Glomerulonephritis • IgA Nephropathy • Immunology • Infectious Disease • Lupus Nephritis • Metabolic Disorders • Movement Disorders • Nephrology • Transplantation

Allogeneic islet transplantation for diabetic patient post-kidney transplant diabetes in 4 cases (TTS 2026) - "Postoperatively, rATG (1 case) or Simulect (3 cases) was administered for immune induction...Anti-inflammatory (etanercept), immunomodulatory, and portal pressure-lowering therapies were applied...Steroid-free immunosuppression (cyclosporine + mycophenolate sodium) was maintained, and kidney function remained stable... Portal vein allogeneic islet transplantation is effective and safe for type 2 diabetes, particularly in kidney transplant recipients on long-term immunosuppression. Even with suboptimal islet counts (<300,000 IEQ), favorable outcomes were achieved. rATG induction may reduce graft loss, and low-toxicity immunosuppressive regimens support long-term graft function.Especially for the fourth patient, a good effect of insulin indenpendence could still be achieved after a low number of islet transplantation."

Clinical • Cerebral Hemorrhage • CNS Disorders • Diabetes • Hematological Disorders • Hypoglycemia • Metabolic Disorders • Transplantation • Type 2 Diabetes Mellitus • Vascular Neurology

Simultaneous Quantification of Mycophenolic Acid and Its Glucuronide Metabolite in PBMCs from Kidney Transplant Recipients by LC-MS/MS. (PubMed, Drug Des Devel Ther) - "Mycophenolic acid (MPA), administered as mycophenolate mofetil (MMF) or enteric-coated mycophenolate sodium (EC-MPS), is the first-line immunosuppressant for kidney transplant patients. The observed weak-to-moderate correlation between plasma and PBMC exposure highlights the inherent limitations of conventional plasma-based TDM for MPA. Collectively, our study provides a feasible approach for monitoring intracellular drug levels and facilitates the optimization of individualized immunosuppressive dosing regimens for renal transplant recipients."

Journal • Transplantation

When the Skin Speaks: Methicillin-resistant Staphylococcus aureus Suprapubic Abscess in a Renal Transplant Recipient. (PubMed, Ann Afr Med) - "We report a 33-year-old male, a live (grandmother to grandson) renal transplant recipient (2019), maintained on tacrolimus, mycophenolate sodium, and steroids, who presented with a 10-day history of low-grade fever and a progressive suprapubic skin lesion...Antibiotic therapy was escalated to daptomycin, with subsequent clinical improvement and healthy granulation tissue formation...MRSA should be suspected in patients with prior healthcare exposure. Early surgical intervention and targeted antimicrobial therapy are essential to prevent complications and graft survival."

Journal • Dermatology • Herpes Zoster • Infectious Disease • Pain • Transplantation • Varicella Zoster

Refractory pemphigus vulgaris temporally associated with mRNA COVID-19 vaccination (CDA 2026) - "Methods/ A 42-year-old woman developed recurrent blistering eruptions on the shoulders approximately four weeks after receiving the second dose of the mRNA-1273 COVID-19 vaccine...Initial skin biopsies were nondiagnostic with nonspecific findings, and empiric treatment with doxycycline did not result in clinical improvement...Adjunctive therapy with mycophenolate sodium and azathioprine failed to achieve disease control...The patient remains in partial remission on rituximab, azathioprine 50 mg daily, and low-dose prednisone... This case adds to the emerging evidence of rare autoimmune blistering disease following mRNA COVID-19 vaccination. While causality cannot be definitively established, the close temporal association, absence of alternative triggers, and refractory disease course support vaccine-associated immune activation. Clinicians should maintain heightened suspicion of PV in persistent post-vaccination blistering eruptions, even without early mucosal..."

Dermatology • Immunology • Infectious Disease • Novel Coronavirus Disease • Pemphigus Vulgaris

INSTEAD: Induction in Sensitized Kidney Transplant Recipients Without Pre-existing Donor-specific antiboDies (clinicaltrials.gov) - P3 | N=244 | Recruiting | Sponsor: University Hospital, Tours | Trial completion date: Mar 2030 ➔ Dec 2030 | Trial primary completion date: Mar 2027 ➔ Dec 2030 | Not yet recruiting ➔ Recruiting

Enrollment open • Trial completion date • Trial primary completion date • Immunology • Transplant Rejection • Transplantation

Xanthogranulomatous Pyelonephritis Due to Mycobacterium Kansasii in an Allograft Kidney (ATC 2026) - "We herein describe a case of a patient with XGP due to Mycobacterium kansasii in an allograft kidney transplant.* A 54 year old male with a history of end stage renal disease due to hypertension status post deceased donor kidney transplant on envarsus, myfortic, and prednisone underwent renal biopsy for acute kidney injury 4 years after transplant...He underwent a nephrectomy of his allograft kidney and was initiated on rifabutin, azithromycin, and ethambutol.* XGP has previously been called the "great imitator" due to similar signs and symptoms of common ailments such as acute pyelonephritis... XGP is an uncommon and severe infection of the kidney. Diagnosis is challenging and if found late can lead to nephrectomy. Renal transplantation is a risk factor for XGP and in patients with early transformation to XGP with negative urine cultures, atypical infections such as mycobacterium should be considered."

Acute Kidney Injury • Cardiovascular • Fibrosis • Hypertension • Immunology • Infectious Disease • Inflammation • Nephrology • Renal Calculi

Secondary FSGS in a Renal Allograft: A Diagnostic Challenge Between Podocytopathy and CNI Toxicity (ATC 2026) - "Maintenance therapy comprised tacrolimus, mycophenolate sodium and prednisone. This case highlights how overlapping morphological features of secondary FSGS and CNI toxicity can complicate post-transplant interpretation. Partial foot-process effacement (<50 %) together with chronic vascular injury supports a secondary or adaptive process rather than recurrent disease. Recognition of these subtleties helps prevent unnecessary escalation of immunosuppression, which may exacerbate nephrotoxicity."

Chronic Kidney Disease • Cognitive Disorders • Diabetes • Diabetic Nephropathy • Fibrosis • Focal Segmental Glomerulosclerosis • Glomerulonephritis • Immunology • Metabolic Disorders • Nephrology • Type 2 Diabetes Mellitus

Belatacept-Induced Colitis: a diagnostic challenge in a kidney transplant patient (ERA 2026) - "Initial immunosuppression included induction with antithymocyte globulin and corticosteroids, followed by maintenance with tacrolimus and mycophenolate sodium (MPA)...At nine months, tacrolimus was dose-reduced due to impaired renal function and replaced with everolimus and prednisone...Due to 75% interstitial fibrosis on protocol biopsy, cyclosporine was replaced with belatacept at 3.5 years post-transplant...Azithromycin was started empirically...Similar cases have been described with abatacept—a related CTLA-4Ig agent—in rheumatoid arthritis patients, showing ulcerative colitis–like presentations...Budesonide MMX® may offer a safe and effective adjunctive therapy. As belatacept becomes more widely used, recognizing this rare but reversible complication is crucial for avoiding misdiagnosis and ensuring prompt, targeted treatment. Image"

Clinical • Cardiovascular • Cytomegalovirus Infection • Fibrosis • Gastroenterology • Gastrointestinal Disorder • Glomerulonephritis • Hematological Disorders • Herpes Simplex • IgA Nephropathy • Immunology • Infectious Disease • Inflammation • Inflammatory Arthritis • Inflammatory Bowel Disease • Nephrology • Pneumonia • Respiratory Diseases • Rheumatoid Arthritis • Transplantation • Ulcerative Colitis

Clinicopathological Features and Outcomes of Mycophenolate Mofetil-Associated Gastrointestinal Injury in Kidney Transplant Recipients (ERA 2026) - "Despite conservative management, 59.8% patients with refractory symptoms required MMF modification (dose reduction, discontinuation, or switching to enteric- coated mycophenolate sodium, azathioprine, or mTOR inhibitors). Conclusion MMF-related changes exhibit a wide spectrum of histological patterns, resembling IBD, GVHD, or other GI diseases. Immunosuppression should be carefully modified due to increased rejection risk, underscoring the need for alternative immunosuppressive strategies in high-risk patients."

Clinical • Cardiovascular • Gastroenterology • Gastrointestinal Disorder • Graft versus Host Disease • Immunology • Inflammation • Inflammatory Bowel Disease • Transplantation

Comparison of Efficacy and Safety of Treatment With a Calcineurin Inhibitor (CNI)Versus a CNI-free Treatment in Renal Transplantation (CIME) (clinicaltrials.gov) - P3 | N=88 | Completed | Sponsor: Centre Hospitalier Universitaire, Amiens | Unknown status ➔ Completed

Trial completion • Nephrology • Renal Disease • Transplantation

REVO-U: A next-generation, gene-editing–free universal CAR-T platform to enable ultra–high-yield manufacturing and identification of early clinical activity in relapsed/refractory DLBCL. (ASCO 2026) - P1 | "Funded by Wondercel Therapeutics, The First Affiliated Hospital of Xi'an Jiaotong University Clinical Trial Registration Number: NCT06662227 Background: We previously invented autologous CAR-T product ciltacabtagene autoleucel (Carvykti) for multiple myeloma, with robust efficacy...In a single-arm, open-label exploratory study, CD19-targeted REVO-UWD19 was given post-lymphodepletion (fludarabine/cyclophosphamide) with short-term oral mycophenolate sodium (EC-MPS) in relapsed/refractory DLBCL patients... REVO-U enables ultra-scalable manufacturing like biologic drugs. Early DLBCL data show no GvHD, with expansion, CRS and responses influenced by lymphodepletion, dose & MPA exposure. Timely EC-MPS adjustment per MPA AUC may be needed for efficacy assurance."

CAR T-Cell Therapy • Clinical • Diffuse Large B Cell Lymphoma • Graft versus Host Disease • Immunology • Infectious Disease • Multiple Myeloma • Neutropenia • Solid Tumor

9416: Immunosuppression regimen reduction in kidney transplantation recipients admitted to the intensive care unit in the setting of septic shock and/or acute respiratory failure: an open multicentric randomized phase IV study (clinicaltrialsregister.eu) - P2/3 | N=212 | Recruiting | Sponsor: Les Hopitaux Universitaires De Strasbourg | Not yet recruiting ➔ Recruiting

Enrollment open • Critical care • Respiratory Diseases • Septic Shock • Transplantation

Pharmacogenetics of Mycophenolic Acid in Patients of African Descent: Underrepresentation of African Data. (PubMed, Clin Transl Sci) - "MPA is the active metabolite formed from the biotransformation of the prodrugs mycophenolate mofetil (MMF) or enteric-coated mycophenolate sodium (EC-MPS). This review evaluates the genes that have been reported to affect MPA exposure as well as highlights conflicting results on the role of these pharmacogenetic variants in different populations. The review highlights the lack of data on African populations and provides justification for their inclusion in the study of MPA pharmacogenetics."

Biomarker • Journal • Review • Immunology • Inflammation • Transplant Rejection • Transplantation

A Rare SAT1 Variant in Early-Onset SLE: Case Report with Case-Control Functional Assay (CRA-AHPA 2026) - "He was treated with pulse methylprednisolone, mycophenolate sodium, and ACE inhibition... We identified a previously unknown variant in SAT1, with evidence demonstrating its association with early-onset SLE in a male diagnosed at an extreme young age. In addition to bioinformatic tools predicting the variant is deleterious, our functional validation studies provide evidence for downstream immune dysregulation. Our report provides important evidence for the causal nature of this rare variant for monogenic lupus."

Case report • Clinical • Absence Seizure Disorder • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • Cardiovascular • CNS Disorders • Developmental Disorders • Epilepsy • Glomerulonephritis • Hematological Disorders • Hypertension • Immunology • Inflammatory Arthritis • Leukopenia • Lupus • Lupus Nephritis • Mental Retardation • Nephrology • Renal Disease • Systemic Lupus Erythematosus • Thrombocytopenia • CCL2 • CXCL1 • IRF7 • MX1 • RSAD2 • SAT1

Not All Malignancy-Associated Membranous Nephropathy Is Secondary: A PLA2R-Negative Case Recurring After Kidney Transplantation (NKF-SCM 2026) - "Proteinuria persisted after nephrectomy despite tacrolimus/prednisone adjustments, and PLA2R remained negative (2019). AKI from tacrolimus–clarithromycin interaction and pancreatitis led to ESRD. He later received a transplant with basiliximab and methylprednisolone induction and tacrolimus/Myfortic maintenance...Although a brief pre-treatment fluctuation occurred, sustained improvement followed rituximab in the setting of ongoing tacrolimus and mycophenolate therapy, supporting continued immune activity even in PLA2R-negative MN. The case challenges assumptions about malignancy-associated MN resolution and underscores the importance of recognizing recurrent non-PLA2R MN in transplant recipients."

Clinical • Cardiovascular • Chronic Kidney Disease • Diabetes • Diabetic Nephropathy • Genito-urinary Cancer • Glomerulonephritis • Hypertension • Metabolic Disorders • Nephrology • Oncology • Pancreatitis • Renal Cell Carcinoma • Renal Disease • Solid Tumor • Transplantation • Type 2 Diabetes Mellitus

Early Cytomegalovirus Viremia in a Kidney Transplant Recipient: A Pitfall from Underdosing Universal Prophylaxis (NKF-SCM 2026) - "ImmuKnow was 217 ng/mL and mycophenolic acid 3.4 µg/mL; mycophenolate sodium was stopped. IV ganciclovir 5 mg/kg q12h was started with marked decline in titers, then switched to oral valganciclovir...CONCLUSION Our case demonstrates a critical aspect of adequate dosing of CMV prophylaxis to avoid early-onset high-titered CMV reactivation. While valganciclovir dosing should be based on eGFR, appropriate dose adjustment should be closely monitored to achieve adequate CMV prophylaxis."

Clinical • Cytomegalovirus Infection • Infectious Disease • Transplantation

Disseminated Cytomegalovirus Infection in a Heart Transplant Recipient: CMV Myocarditis Mimicking Antibody Mediated Rejection (ISHLT 2026) - "Immunosuppression included mycophenolate sodium, prednisone, and cyclosporine...Two days later, endoscopy showed esophageal ulcers consistent with CMV, prompting intravenous ganciclovir...CMV detection on biopsy is rare. This case shows CMV myocarditis mimicking rejection, emphasizing early diagnostic accuracy to avoid inappropriate immunosuppression."

Clinical • Antibody-mediated Rejection • Cardiomyopathy • Cardiovascular • Cytomegalovirus Infection • Heart Failure • Infectious Disease • Inflammation • Transplantation

West Nile Virus Encephalitis in a Lung Transplant Patient (ISHLT 2026) - "Remdesivir is an antiviral agent that has been shown to have in vitro activity against WNV with potential benefit in vivo.Case Report We present a 74-year-old male patient who underwent left single lung transplant in March 2025 for idiopathic pulmonary fibrosis...His immunosuppression protocol was tacrolimus (target 15-20 micrograms/L), mycophenolate sodium 720 mg BID, and prednisone. He was on voriconazole for fungal infection with A. fumigatus and Cladosporium species...On D29 a decision was made to withdraw life-sustaining therapies and the patient died.Summary The current treatments available for WNV encephalitis are currently limited to supportive care. Morbidity and mortality in solid organ transplant recipients are high, requiring further investigation of alternate strategies including hyperimmune gammaglobulin and effective antiviral therapy."

Clinical • CNS Disorders • Idiopathic Pulmonary Fibrosis • Immunology • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Solid Organ Transplantation • Transplantation

Efficacy and safety of mycophenolate sodium enteric coated tablets after living donor kidney transplantation (ChiCTR) - P4 | N=25 | Recruiting | Sponsor: The First Affiliated Hospital of Xi'an Jiaotong University; The First Affiliated Hospital of Xi'an Jiaotong University

New P4 trial • Transplantation

Evaluation of hematocrit-adjusted conversion strategies for mycophenolic acid and tacrolimus monitoring using volumetric absorptive microsampling in lung and renal transplant recipients. (PubMed, J Pharm Pharm Sci) - "Adult transplant recipients receiving mycophenolate mofetil or mycophenolate sodium were prospectively enrolled. This validated VAMS-based approach offers a minimally invasive and clinically applicable alternative to venous sampling for MPA and TAC monitoring. Incorporating individualized Hct adjustments improves predictive performance, supporting conditional integration of VAMS into routine TDM."

Journal • Transplantation

MPAExpo-LM: Fine-Tuned Large Language Model for Mycophenolic Acid Exposure Estimation After Renal Transplantation. (PubMed, IEEE J Biomed Health Inform) - "An accurate estimation of mycophenolic acid (MPA) exposure after renal transplantation is important for reducing acute rejection in patients treated with mycophenolate mofetil (MMF) or enteric-coated mycophenolate sodium (MPS). In the subsequent multi-center validation, the model demonstrated robust generalization, achieving RMSEs of 7.342 mg·h/L (three points) and 7.281 mg·h/L (four points). Via reinforcement fine-tuning, the model demonstrates strong generalization capability in cross-hospital tests."

Journal • Nephrology • Transplant Rejection • Transplantation